{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:27:51Z","timestamp":1783970871753,"version":"3.55.0"},"reference-count":38,"publisher":"Bentham Science Publishers Ltd.","issue":"46","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,4,26]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Targeting the renin-angiotensin-aldosterone axis is one of the most important therapeutic\npathways for blood pressure control, renal and cardiovascular protection.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p> In this review, the new nonsteroidal mineralcorticoid receptor antagonists will be presented with a\nspecial focus on finerenone and its randomized controlled trials along with an introduction to the clinically promising\naldosterone synthase inhibitors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>We conducted an in-detail review of the literature in order to draft a narrative review on the field.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Development of new anti-aldosterone agents focusing on the diverse components of aldosterone production\nand action is now taking place. Nonsteroidal mineral\u03bfcorticoid receptor antagonists are safe and effective\ntherapeutic solutions with finerenone being the most well-studied agent with promising clinical data extending its\nefficacy in diabetes mellitus, chronic kidney disease and heart failure. Aldosterone synthase inhibitors impact the\nhormonal balance but there are still limitations regarding the duration of action and adverse effect of the glycolcorticoid\naxis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Novel third-generation, nonsteroidal mineralocorticoid receptor antagonists seem to offer great\nadvantages, which may lead to a wider use of mineralocorticoid receptor antagonists. Future randomized controlled\ntrials are needed to evaluate significant perspectives.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666190222145116","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T11:33:01Z","timestamp":1551094381000},"page":"5548-5554","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Future Anti-aldosterone Agents"],"prefix":"10.2174","volume":"24","author":[{"given":"Kyriakos","family":"Dimitriadis","sequence":"first","affiliation":[{"name":"First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayotis","family":"Iliakis","sequence":"additional","affiliation":[{"name":"First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Kasiakogias","sequence":"additional","affiliation":[{"name":"First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Andrikou","sequence":"additional","affiliation":[{"name":"First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Leontsinis","sequence":"additional","affiliation":[{"name":"First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Konstantinidis","sequence":"additional","affiliation":[{"name":"First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tousoulis","sequence":"additional","affiliation":[{"name":"First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2012.249","volume":"9","author":"Sev\u00e1 Pess\u00f4a B.","year":"2013","unstructured":"Sev\u00e1 Pess\u00f4a B, van der Lubbe N, Verdonk K, Roks AJ, Hoorn EJ, Danser AH. Nat Rev Nephrol, Key developments in renin-angiotensin-aldosterone system inhibition., 2013, 9, 26-36,","journal-title":"Nat Rev Nephrol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski P.","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD. Eur Heart J, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC., 2016, 37, 2129-2200,","journal-title":"Eur Heart J"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"Williams B.","year":"2018","unstructured":"Williams B, Mancia G, Spiering W. Eur Heart J, 2018 ESC\/ESH Guidelines for the management of arterial hypertension., 2018, 39, 3021-3104,","journal-title":"Eur Heart J"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2003.10.011","volume":"217","author":"Bassett M.H.","year":"2004","unstructured":"Bassett MH, White PC, Rainey WE. Mol Cell Endocrinol, The regulation of aldosterone synthase expression., 2004, 217, 67-74,","journal-title":"Mol Cell Endocrinol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrendo.2009.263","volume":"6","author":"Tomaschitz A.","year":"2010","unstructured":"Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Nat Rev Endocrinol, Aldosterone and arterial hypertension., 2010, 6, 83-93,","journal-title":"Nat Rev Endocrinol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/HYPERTENSIONAHA.108.111211","volume":"52","author":"Ruilope L.M.","year":"2008","unstructured":"Ruilope LM. Hypertension, Aldosterone, hypertension, and cardiovascular disease: An endless story., 2008, 52, 207-208,","journal-title":"Hypertension"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/1570161115666170426145612","volume":"16","author":"Doumas M.","year":"2017","unstructured":"Doumas M, Boutari C, Tsioufis C, Dimitriadis K, Triantafyllou A, Douma S. Curr Vasc Pharmacol, Clinical Value of Measuring the Renin\/Aldosterone Levels: Optimising the Management of Uncontrolled\/Resistant Hypertension., 2017, 16, 10-14,","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"642416","DOI":"10.4061\/2011\/642416","volume":"2011","author":"Tsioufis C.","year":"2011","unstructured":"Tsioufis C, Kordalis A, Flessas D. Int J Hypertens, Pathophysiology of resistant hypertension: the role of sympathetic nervous system., 2011, 2011, 642416-,","journal-title":"Int J Hypertens"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000346817","volume":"3","author":"Tsioufis C.","year":"2013","unstructured":"Tsioufis C, Tsiachris D, Kasiakogias A. Cardiorenal Med, Preclinical cardiorenal interrelationships in essential hypertension., 2013, 3, 38-47,","journal-title":"Cardiorenal Med"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-44-1-1","volume":"44","author":"Conn J.W.","year":"1956","unstructured":"Conn JW, Louis LH. Ann Intern Med, Primary aldosteronism, a new clinical entity., 1956, 44, 1-15,","journal-title":"Ann Intern Med"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(57)90970-4","volume":"272","author":"Conn J.W.","year":"1957","unstructured":"Conn JW, Fajans SS, Louis LH, Streeten DH, Johnson RD. Lancet, Intermittent aldosteronism in periodic paralysis; dependence of attacks on retention of sodium, and failure to induce attacks by restriction of dietary sodium., 1957, 272, 802-805,","journal-title":"Lancet"},{"key":"ref=12","author":"Hargovan M.","year":"2014","unstructured":"Hargovan M, Ferro A. JRSM Cardiovasc Dis, Aldosterone synthase inhibitors in hypertension: current status and future possibilities., 2014, 272, 802-,","journal-title":"JRSM Cardiovasc Dis"},{"key":"ref=13","first-page":"827","volume":"12","author":"Tamargo M.","year":"2017","unstructured":"Tamargo M, Tamargo J. Expert Opin Drug Discov, Future drug discovery in renin-angiotensin-aldosterone system intervention., 2017, 12, 827-848,","journal-title":"Expert Opin Drug Discov"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1042\/CS20140432","volume":"128","author":"Brem A.S.","year":"2015","unstructured":"Brem AS, Gong R. Clin Sci (Lond), Therapeutic targeting of aldosterone: A novel approach to the treatment of glomerular disease., 2015, 128, 527-535,","journal-title":"Clin Sci (Lond)"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","volume":"116","author":"Oparil S.","year":"2015","unstructured":"Oparil S, Schmieder RE. Circ Res, New approaches in the treatment of hypertension., 2015, 116, 1074-1095,","journal-title":"Circ Res"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2015.07.006","volume":"154","author":"Deinum J.","year":"2015","unstructured":"Deinum J, Riksen NP, Lenders JW. Pharmacol Ther, Pharmacological treatment of aldosterone excess., 2015, 154, 120-133,","journal-title":"Pharmacol Ther"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)90065-X","volume":"78","author":"Pitt B.","year":"1996","unstructured":"Pitt B, Zannad F, Remme WJ. Am J Cardiol, Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])., 1996, 78, 902-907,","journal-title":"Am J Cardiol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","volume":"118","author":"Pitt B.","year":"2008","unstructured":"Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Circulation, Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)., 2008, 118, 1643-1650,","journal-title":"Circulation"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"Weinberger M.H.","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ. Am J Hypertens, Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension., 2002, 15, 709-716,","journal-title":"Am J Hypertens"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","volume":"24","author":"Kolkhof P.","year":"2015","unstructured":"Kolkhof P, Nowack C, Eitner F. Curr Opin Nephrol Hypertens, Nonsteroidal antagonists of the mineralocorticoid receptor., 2015, 24, 417-424,","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"B\u00e4rfacker L.","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A. ChemMedChem, Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases., 2012, 7, 1385-1403,","journal-title":"ChemMedChem"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"Pitt B.","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P. Eur Heart J, Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial., 2013, 34, 2453-2463,","journal-title":"Eur Heart J"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","volume":"350","author":"Kolkhof P.","year":"2012","unstructured":"Kolkhof P, Borden SA. Mol Cell Endocrinol, Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics., 2012, 350, 310-317,","journal-title":"Mol Cell Endocrinol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"Bakris G.L.","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC. JAMA, Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial., 2015, 314, 884-894,","journal-title":"JAMA"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"Katayama S.","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M. J Diabetes Complications, A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy., 2017, 31, 758-765,","journal-title":"J Diabetes Complications"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"Filippatos G.","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M. Eur Heart J, A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease., 2016, 37, 2105-2114,","journal-title":"Eur Heart J"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","volume":"17","author":"Pitt B.","year":"2015","unstructured":"Pitt B, Anker SD, B\u00f6hm M. Eur J Heart Fail, Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): A randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease., 2015, 17, 224-232,","journal-title":"Eur J Heart Fail"},{"key":"ref=28","author":"Sato N","year":"2016","unstructured":"Sato N, Ajioka M, Yamada T. A Randomized Controlled Study of Finerenone vs., ,  80: 1113-22., 2016","journal-title":"A Randomized Controlled Study of Finerenone vs"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ndt\/gfs388","volume":"28","author":"Azizi M.","year":"2013","unstructured":"Azizi M, Amar L, Menard J. Nephrol Dial Transplant, Aldosterone synthase inhibition in humans., 2013, 28, 36-43,","journal-title":"Nephrol Dial Transplant"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","volume":"29","author":"Mulder P.","year":"2008","unstructured":"Mulder P, Mellin V, Favre J. Eur Heart J, Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: A comparison with spironolactone., 2008, 29, 2171-2179,","journal-title":"Eur Heart J"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/ml4000172","volume":"4","author":"Abdel-Magid A.F.","year":"2013","unstructured":"Abdel-Magid AF. ACS Med Chem Lett, Aldosterone synthase inhibitors: targeting chronic kidney disease and diabetic nephropathy., 2013, 4, 157-158,","journal-title":"ACS Med Chem Lett"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1021\/jm500140c","volume":"57","author":"Yin L.","year":"2014","unstructured":"Yin L, Hu Q, Emmerich J. J Med Chem, Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors., 2014, 57, 5179-5189,","journal-title":"J Med Chem"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"Amar L.","year":"2010","unstructured":"Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF. Hypertension, Aldosterone synthase inhibition with LCI699: A proof-of-concept study in patients with primary aldosteronism., 2010, 56, 831-838,","journal-title":"Hypertension"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","volume":"124","author":"Calhoun D.A.","year":"2011","unstructured":"Calhoun DA, White WB, Krum H. Circulation, Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial., 2011, 124, 1945-1955,","journal-title":"Circulation"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0b013e328363570c","volume":"31","author":"Schumacher C.D.","year":"2013","unstructured":"Schumacher CD, Steele RE, Brunner HR. J Hypertens, Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy., 2013, 31, 2085-2093,","journal-title":"J Hypertens"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","volume":"15","author":"Karns A.D.","year":"2013","unstructured":"Karns AD, Bral JM, Hartman D, Peppard T, Schumacher C. J Clin Hypertens (Greenwich), Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension., 2013, 15, 186-192,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/HJH.0b013e32835d6d49","volume":"31","author":"Amar L.","year":"2013","unstructured":"Amar L, Azizi M, Menard J, Peyrard S, Plouin PF. J Hypertens, Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism., 2013, 31, 624-629,","journal-title":"J Hypertens"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2174\/1381612823666170206154706","volume":"23","author":"Faselis C.","year":"2017","unstructured":"Faselis C, Boutari C, Doumas M, Imprialos K, Stavropoulos K, Kokkinos P. Curr Pharm Des, Novel drugs for hypertension and heart failure: struggling for a place under the sum., 2017, 23, 1540-1550,","journal-title":"Curr Pharm Des"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T21:43:54Z","timestamp":1558820634000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170163\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":38,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2019,4,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190222145116","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}